484 related articles for article (PubMed ID: 29164820)
21. Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages
Lefere S; Puengel T; Hundertmark J; Penners C; Frank AK; Guillot A; de Muynck K; Heymann F; Adarbes V; Defrêne E; Estivalet C; Geerts A; Devisscher L; Wettstein G; Tacke F
J Hepatol; 2020 Oct; 73(4):757-770. PubMed ID: 32360434
[TBL] [Abstract][Full Text] [Related]
22. The effects of herbal composition Gambigyeongsinhwan (4) on hepatic steatosis and inflammation in Otsuka Long-Evans Tokushima fatty rats and HepG2 cells.
Yoon S; Kim J; Lee H; Lee H; Lim J; Yang H; Shin SS; Yoon M
J Ethnopharmacol; 2017 Jan; 195():204-213. PubMed ID: 27845265
[TBL] [Abstract][Full Text] [Related]
23. Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists.
Boeckmans J; Natale A; Rombaut M; Buyl K; Cami B; De Boe V; Heymans A; Rogiers V; De Kock J; Vanhaecke T; Rodrigues RM
Cell Biol Toxicol; 2021 Apr; 37(2):293-311. PubMed ID: 32613381
[TBL] [Abstract][Full Text] [Related]
24. Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study.
Goyal O; Nohria S; Goyal P; Kaur J; Sharma S; Sood A; Chhina RS
Sci Rep; 2020 Dec; 10(1):21117. PubMed ID: 33273703
[TBL] [Abstract][Full Text] [Related]
25. Cangju Qinggan Jiangzhi Decoction Reduces the Development of NonAlcoholic Steatohepatitis and Activation of Kupffer Cells.
Cheng Y; Chen T; Ping J; Chen J
Cell Physiol Biochem; 2018; 48(3):971-982. PubMed ID: 30036865
[TBL] [Abstract][Full Text] [Related]
26. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Staels B; Rubenstrunk A; Noel B; Rigou G; Delataille P; Millatt LJ; Baron M; Lucas A; Tailleux A; Hum DW; Ratziu V; Cariou B; Hanf R
Hepatology; 2013 Dec; 58(6):1941-52. PubMed ID: 23703580
[TBL] [Abstract][Full Text] [Related]
27. Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice.
Takatani N; Kono Y; Beppu F; Okamatsu-Ogura Y; Yamano Y; Miyashita K; Hosokawa M
Biochem Biophys Res Commun; 2020 Jul; 528(2):305-310. PubMed ID: 32475638
[TBL] [Abstract][Full Text] [Related]
28. Antiretroviral drug-induced endothelial dysfunction is improved by dual PPARα/γ stimulation in obesity.
Kamau F; Strijdom H; Mwangi P; Blackhurst D; Imperial E; Salie R
Vascul Pharmacol; 2019 Oct; 121():106577. PubMed ID: 31284000
[TBL] [Abstract][Full Text] [Related]
29. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
Cong WN; Tao RY; Tian JY; Liu GT; Ye F
Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
[TBL] [Abstract][Full Text] [Related]
30. Amelioration by chicory seed extract of diabetes- and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) via modulation of PPARα and SREBP-1.
Ziamajidi N; Khaghani S; Hassanzadeh G; Vardasbi S; Ahmadian S; Nowrouzi A; Ghaffari SM; Abdirad A
Food Chem Toxicol; 2013 Aug; 58():198-209. PubMed ID: 23603006
[TBL] [Abstract][Full Text] [Related]
31. Fenofibrate alleviates NAFLD by enhancing the PPARα/PGC-1α signaling pathway coupling mitochondrial function.
Wang X; Wang J; Ying C; Xing Y; Su X; Men K
BMC Pharmacol Toxicol; 2024 Jan; 25(1):7. PubMed ID: 38173037
[TBL] [Abstract][Full Text] [Related]
32. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis.
Matsumoto M; Hada N; Sakamaki Y; Uno A; Shiga T; Tanaka C; Ito T; Katsume A; Sudoh M
Int J Exp Pathol; 2013 Apr; 94(2):93-103. PubMed ID: 23305254
[TBL] [Abstract][Full Text] [Related]
33. Hepatic vagus nerve regulates Kupffer cell activation via α7 nicotinic acetylcholine receptor in nonalcoholic steatohepatitis.
Nishio T; Taura K; Iwaisako K; Koyama Y; Tanabe K; Yamamoto G; Okuda Y; Ikeno Y; Yoshino K; Kasai Y; Okuno M; Seo S; Sakurai T; Asagiri M; Hatano E; Uemoto S
J Gastroenterol; 2017 Aug; 52(8):965-976. PubMed ID: 28044208
[TBL] [Abstract][Full Text] [Related]
34. Discovery of novel dual PPARα/δ agonists based on benzimidazole scaffold for the treatment of non-alcoholic fatty liver disease.
Li Z; Xu Y; Cai Z; Wang X; Ren Q; Zhou Z; Xie R
Bioorg Chem; 2020 Jun; 99():103803. PubMed ID: 32251945
[TBL] [Abstract][Full Text] [Related]
35. Hydrogen-rich water protects against liver injury in nonalcoholic steatohepatitis through HO-1 enhancement via IL-10 and Sirt 1 signaling.
Li SW; Takahara T; Que W; Fujino M; Guo WZ; Hirano SI; Ye LP; Li XK
Am J Physiol Gastrointest Liver Physiol; 2021 Apr; 320(4):G450-G463. PubMed ID: 33439102
[TBL] [Abstract][Full Text] [Related]
36. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
[TBL] [Abstract][Full Text] [Related]
37. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
38. Morphological and functional characterization of non-alcoholic fatty liver disease induced by a methionine-choline-deficient diet in C57BL/6 mice.
Itagaki H; Shimizu K; Morikawa S; Ogawa K; Ezaki T
Int J Clin Exp Pathol; 2013; 6(12):2683-96. PubMed ID: 24294355
[TBL] [Abstract][Full Text] [Related]
39. Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease.
Hong XZ; Li LD; Wu LM
Clin Exp Pharmacol Physiol; 2007; 34(1-2):27-35. PubMed ID: 17201732
[TBL] [Abstract][Full Text] [Related]
40. Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis.
Vijayakumar A; Okesli-Armlovich A; Wang T; Olson I; Seung M; Kusam S; Hollenback D; Mahadevan S; Marchand B; Toteva M; Breckenridge DG; Trevaskis JL; Bates J
Hepatol Commun; 2022 Sep; 6(9):2298-2309. PubMed ID: 35735253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
